Please assess the completion status of the following clinical trial:

Trial Title: Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~  1. Documentation of HIV-1 infection, by either two positive ELISAs or two discrepant ELISAs with a confirmatory positive Western Blot~ 2. Documentation of prior HSV-2 infection by Focus Kalon ELISA~ 3. Absolute CD4+ T-cell count of greater than or equal to 300 and less than or equal to 400 cells/microliter within 30 days prior to randomization~ 4. All participants must be receiving Cotrimoxazole prophylaxis as part of standard care unless contraindicated~ 5. Age at least 18 years and above~ 6. Laboratory values (within 30 days prior to randomization)~     1. Aspartate transaminase (AST) no more than five times the upper limit of normal (ULN)~    2. Total bilirubin no more than 2 times ULN~    3. Creatinine no more than 2.0 mg/dL~    4. Platelet count at least 50 000/microliter~    5. Hemoglobin at least 8g/dL~ 7. Written informed consent~EXCLUSION CRITERIA:~1. Concurrent malignancy or any other disease state requiring cytotoxic chemotherapy~2. Symptomatic for significant HIV-related illnesses (WHO stage III or IV), such as opportunistic infections and malignancies other than mucocutaneous Kaposi's sarcoma. A history of AIDS defining opportunistic infections other than mucocutaneous Kaposi's sarcoma or candida or treated tuberculosis~3. Active HSV-2 disease as suggested by painful genital ulcer disease at time of screening or enrollment~4. Current use of antiretroviral medications or Preventing Mother-to-Child Transmission (PMTCT) use of antiretrovirals within the previous 6 months~5. Significant cardiac, pulmonary, kidney, rheumatologic, gastrointestinal, or CNS disease as detectable on routine medical history, physical examination, or screening laboratory studies.~6. Psychiatric illness that, in the opinion of the PI, might interfere with the study compliance.~7. Active substance abuse or history of prior substance abuse that may interfere with protocol compliance or patient safety.~8. CD4+ count less than 300 or more than 400 cells/microliter.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Acyclovir 400mg tablet twice daily (Type: ACTIVE_COMPARATOR): None
- Placebo tablet twice daily (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).